Group 1 - The company GUANZE MEDICAL (02427) announced a share acquisition agreement with the offeror, Fude (Hong Kong) Investment Holdings Limited, to purchase 699 million shares, representing approximately 73.60% of the company's total issued share capital, for a total consideration of HKD 175 million, equating to HKD 0.25 per share [1] - Following the completion of the acquisition, the offeror will hold 699 million shares, which will constitute approximately 73.60% of the company's issued share capital [1] - The offeror is required to make a mandatory unconditional cash offer to acquire all remaining shares of the company at a price of HKD 0.25 per share, which represents an approximately 84.0% discount compared to the last trading price of HKD 1.560 per share on January 26, 2026 [1] Group 2 - The offeror is a limited liability company registered in Hong Kong, primarily engaged in stock and equity investments, with ownership held by Mr. Zhang Jun (94%) and Ms. Tao Meiying (6%) [2] - The offeror is wholly owned by Fude Holdings (Group) Limited, which is in turn owned by Shenzhen Jun De Investment Co., Ltd., Mr. Zhang, and Ms. Tao through various ownership stakes [2] - An independent financial advisor, Softbank China Hong Kong Securities Limited, has been appointed to provide advice to the independent board committee regarding the fairness and reasonableness of the offer [2] Group 3 - The company has applied to the Stock Exchange for the resumption of trading of its shares starting from 9:00 AM on February 12, 2026 [3]
GUANZE MEDICAL(02427)获富德(香港)投资控股折让约84.0%提现金要约 2月12日复牌